Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483829 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4803286 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL20210 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL23904091 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL3670962 | 0.80 | MAPT (0.47) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL19055 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL2633979 | 0.80 | KDM4E (0.59) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL4804914 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL4804922 | 0.80 | KDM4E (0.59) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL188710 | 0.80 | ALDH1A1 (0.63) | SMN1; SMN2MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 991 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115304543-B | Preparation method and product of aryl sulfonamide containing norbornenyl and application of aryl sulfonamide | 南京林业大学 | 2024-08-20 | — | — | CN | claimed |
| CN-115304543-A | Preparation method of aryl sulfonamide containing norbornenyl, product and application thereof | 南京林业大学 | 2022-11-08 | — | — | CN | claimed |
| CN-102603630-A | O-aminobenzoic acid sulfonylation derivative as well as preparation method and application thereof | UNIV BEIJING SCIENCE & TECH | 2012-07-25 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260116910-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-0070481-B1 | PHOTOGRAPHIC ELEMENTS EMPLOYING NONDIFFUSIBLE PYRIDYLAZO(DIALKYLAMINO)PHENOL MAGENTA DYE-RELEASING COMPOUNDS OR PRECURSORS THEREOF | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-10 | — | — | EP | disclosed |
| EP-0119050-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1984-09-19 | — | — | EP | disclosed |
| EP-0070481-A1 | Photographic elements employing nondiffusible pyridylazo(dialkylamino)phenol magenta dye-releasing compounds or precursors thereof | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1983-01-26 | — | — | EP | disclosed |
| US-4368249-A | Photographic products and processes employing novel nondiffusible pyridylazo(dialkylamino)phenol magenta dye-releasing compounds and precursors thereof | EASTMAN KODAK COMPANY (US) | 1983-01-11 | — | — | US | disclosed |
| US-4367174-A | Photographic products and processes employing novel nondiffusible pyridylazo(dialkylamino)phenol magenta dye-releasing compounds and precursors thereof | EASTMAN KODAK COMPANY (US) | 1983-01-04 | — | — | US | disclosed |
| US-4357410-A | Photographic products and processes employing novel nondiffusible pyridylazo(dialkylamino) phenol magenta dye-releasing compounds and precursors thereof | EASTMAN KODAK COMPANY (US) | 1982-11-02 | — | — | US | disclosed |
| US-4273706-A | Nondiffusible heterocyclylazonaphthol dye-releasing compounds | EASTMAN KODAK COMPANY (US) | 1981-06-16 | — | — | US | disclosed |
| US-4207104-A | DIFFUSION TRANSFER TO FORM METALLIZED DYE IMAGE OF EXCELLENT STABILITY | EASTMAN KODAK COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4204870-A | METALLIZED DYES | EASTMAN KODAK COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | SMN1; SMN2 4729/4885MAPT 2797/4885POLB 1807/4885 |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | SMN1; SMN2 1060/4885MAPT 3508/4885POLB 342/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | SMN1; SMN2 3395/4885MAPT 4813/4885POLB 2549/4885 |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CYP51A1, CYP11B2, CYP11B1 | SMN1; SMN2 4385/4885MAPT 2778/4885POLB 4103/4885 |
| US-20260116910-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | NR1H3, NR1H2, CPT1A | SMN1; SMN2 1522/4885MAPT 3948/4885POLB 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.